Eli Lilly Turns to Tau Proteins with AC Immune Alzheimer’s Deal
By Subham Nandi
Pharma Deals Review: Vol 2018 Issue 12 (Table of Contents)
Published: 28 Dec-2018
DOI: 10.3833/pdr.v2018.i12.2389 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Despite several high-profile setbacks, Eli Lilly has agreed to in-license AC Immune’s tau aggregation inhibitors for the treatment of Alzheimer’s disease and other neurodegenerative diseases for a total potential deal value of CHF1840 M (US$1858...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS